Last Update: Nov 06, 2026 A Phase 1, Single-dose, Open-label Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Healthy Participants With Normal Renal Function ClinicalTrials.gov Identifier: [NCT07797322](https://clinicaltrials.gov/ct2/show/NCT07797322) Novartis Reference Number:CPKN605A02104 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The purpose of this trial is to assess any potential exposure increases of PKN605 in participants with reduced renal function to support decisions on participant eligibility and dosing in subsequent clinical trials of PKN605. This is a Phase 1, single-dose, open-label, non-randomized renal impairment study to assess the PK after a single administration of PKN605 in participants with moderate (Group 1) and severe (Group 2) renal impairment and matched healthy participants with normal renal function (Group 3). Condition Participants With Moderate and Severe Renal Impairment and Healthy Participants Phase Phase1 Overall Status Recruiting Number of Participants40 Start Date Oct 01, 2026 Completion Date Mar 02, 2027 Gender All Age(s) 18 Years - 80 Years (Adult, Older Adult) ## Interventions Drug ### PKN605 PKN605 orally as a tablet under fasted conditions ## Eligibility Criteria Inclusion Criteria: All participants (Group 1, 2 \\& 3) \* Male and female participants 18 to 80 years of age (inclusive). \* Weigh at least 50 kg with a body mass index (BMI) within the range of 18 to 42.0 kg/m2, inclusive, at Screening. Participants with moderate and severe RI (Group 1 \\& 2) \* Have impaired renal function as determined by the mean eGFR calculated using the CKD EPI Creatinine - Cystatin C equation (2021) (refer to Section 8.5.1 for equation), and fall into one of the following groups: \* Group 1: moderate RI; eGFR 30 to 60 mL/min, inclusive. \* Group 2: severe RI; eGFR \\<30 mL/min, not requiring dialysis. \* \\\*The mean eGFR will be calculated from 2 values: one obtained at Screening and a second obtained at least 72 hours later, either at Screening or at the Baseline visit. The mean of these 2 values will be used to assign the renal impairment group. \* Have stable renal function with no clinically significant change (no change ≥25% from Screening 1 to Screening 2 or Baseline value) in renal status prior to first dosing of study treatment as determined by the Investigator and is not currently or has not been previously on hemodialysis for at least 1 year. Healthy control participants (Group 3) \* Each healthy participant must match the age (±10 years), body weight (±15%), and sex of an individual participant in Group 1 and/or Group 2. \* Has normal renal function with eGFR ≥90 mL/min, determined using the CKD-EPI Creatinine - Cystatin C equation (2021) at Screening. Exclusion Criteria: All participants (Group 1, 2 \\& 3) \* Women of childbearing potential (as defined in the protocol) need to use an effective contraception method during the course of this trial. \* History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants such as: \* Clinically significant ECG abnormalities that, in the opinion of the Investigator, would place the participant at increased risk. \* Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree atrioventricular block without a pacemaker. \* History of long QT syndrome or known family history of ventricular arrhythmia or sudden cardiac death. \* QT interval corrected by Fridericia's formula (QTcF) \\>450 milliseconds (ms) for males and \\>460 ms for females, unless considered not clinically significant and not associated with increased arrhythmic risk by the Investigator, with appropriate safety oversight; QTcF must not exceed 470 ms in males and 480 ms in females. \* Use of agents known to prolong the QT interval unless they can be discontinued for the duration of study. \* Initiation or dose adjustment within \\<4 weeks of screening of medications known to cause acute changes in eGFR (e.g., angiotensin-converting-enzyme \\\[ACE\\\] inhibitors, angiotensin II receptor blockers \\\[ARBs\\\], sodium/glucose cotransporter 2 \\\[SGLT2\\\] inhibitors, diuretics, nonsteroidal anti-inflammatory drugs \\\[NSAIDs\\\]). Note: NSAIDs are excluded for use in participants with moderate and severe renal impairment (refer to Exclusion criterion 23). \* Renal transplant recipients or has had a nephrectomy. Participants with moderate and severe RI (Group 1 \\& 2) \* Participants requiring dialysis. \* Participants taking erythropoiesis-stimulating agents (ESAs) within the last 6 months of Screening and until end of study (EoS) visit. Healthy control participants (Group 3) • History or presence of impaired renal function as indicated by clinically significantly abnormal creatinine or blood urea nitrogen and/or urea values, or abnormal urinary constituents or eGFR \\<90 mL/min in medical history or at Screening. Other protocol-defined inclusion/exclusion criteria may apply United States #### University of Miami Recruiting Miami,Florida,33136,United States ###### Dyal Garg Phone: [+1 305 355 5111]() Email: ###### Richard A Preston #### Orlando Clinical Research Center Inc Recruiting Orlando,Florida,32809,United States ###### Cindy Brown Email: ###### Thomas C Marbury #### Genesis Clinical Research Recruiting Tampa,Florida,33614,United States ###### Jesus Navarro ###### Lauren Navarro Email: ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ 1-888-669-6682](tel:1-888-669-6682) Email: